IDO1 and melanoma: Holmgaard et al. also found similar results with anti-PD-1 treatment: IDO−/− mice with B16 melanoma had a significantly reduced tumor burden and improved survival, suggesting that IDO inhibition could be a potential adjuvant to current immunotherapy [45].